Skip to main content

Crosstalks between inflammasome and autophagy in cancer


Both inflammasomes and autophagy have important roles in the intracellular homeostasis, inflammation, and pathology; the dysregulation of these processes is often associated with the pathogenesis of numerous cancers. In addition, they can crosstalk with each other in multifaceted ways to influence various physiological and pathological responses, including cancer. Multiple molecular mechanisms connect the autophagy pathway to inflammasome activation and, through this, may influence the outcome of pro-tumor or anti-tumor responses depending on the cancer types, microenvironment, and the disease stage. In this review, we highlight the rapidly growing literature on the various mechanisms by which autophagy interacts with the inflammasome pathway, to encourage additional applications in the context of tumors. In addition, we provide insight into the mechanisms by which pathogen modulates the autophagy-inflammasome pathway to favor the infection-induced carcinogenesis. We also explore the challenges and opportunities of using multiple small molecules/agents to target the autophagy/inflammasome axis and their effects upon cancer treatment. Finally, we discuss the emerging clinical efforts assessing the potential usefulness of targeting approaches for either autophagy or inflammasome as anti-cancer strategies, although it remains underexplored in terms of their crosstalks.


Autophagy is an intracellular catabolic process and plays a crucial role in the maintenance of homeostasis in a variety of biological processes. Depending on the disease stage and the tumor microenvironment, autophagy plays a dual role in cancer; it can either promote oncogenesis or suppress tumor growth. In most cancers, autophagy facilitates tumorigenesis by regulating mitochondrial quality control and the supply of nutrients required for cancer cell growth under nutrient-deprived conditions [1,2,3,4]. However, the induction of autophagy may suppress tumor growth through maintaining cellular integrity, preventing cellular damage, and attenuating cell stemness [4, 5]. Inflammasomes are large protein complexes required for the secretion of mature interleukin (IL)-1β and IL-18, and pyroptosis, an inflammatory, caspase-1-dependent form of programmed cell death [6]. The transcriptional regulation of inflammasome-associated pattern recognition receptors plays a critical role in cancer [7]. Dysregulation of NOD-like receptor (NLR) signaling is strongly linked to chronic inflammation and subsequent tumor development [8, 9]. However, inflammasome activation is also associated with a lower risk of colitis-associated colon cancer [10].

Apart from its role in diverse physiological and pathological conditions, the crosstalk between autophagy and inflammasomes is crucial in the pathogenesis of cancer [6, 11]. In general, autophagy is regarded as a safety mechanism counteracting hyperactivation of inflammasomes and chronic inflammation-induced cancer [12]. Defects in canonical autophagy or mitophagy can lead to pathological responses and necrosis, promoting chronic inflammation and tumorigenesis [12, 13]. Additionally, autophagy levels have been associated with cell death fate and cell clearance [12]. Autophagic cancer cell death can trigger autocrine or paracrine ATP signaling through purinergic receptors, activating NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome and IL-1β secretion [14]. In particular, ATP derived from dying cells is a strong mediator of pro-inflammatory responses in macrophages found in the tumor microenvironment, augmenting anti-tumor immune responses [14]. Thus, autophagy regulation is critical for tumor immune surveillance and cancer cell death [12].

In this review, we summarize the current knowledge regarding the interplay between autophagy and inflammasome activation in cancer. Particularly, we provide a brief overview of autophagy, mitophagy, and inflammasome pathways and outline various signaling molecules and molecular pathways that regulate the crosstalk between two processes to get more insights into their implications in cancers. In addition, we discuss several findings that pathogens modulate autophagy-inflammasome axis to facilitate infection-induced carcinogenesis. We also summarize the promising anti-cancer pharmacological agents that have been tested in vitro or in vivo and provide examples of clinical translation.

Overview of autophagy and inflammasomes

Autophagy plays a dynamic role in different stages of tumorigenesis, either promoting or suppressing tumor development and progression [15, 16]. The molecular mechanisms underlying autophagy and selective autophagy have been comprehensively reviewed previously [17,18,19]. Herein, we provide a brief overview of autophagy and mitophagy, and inflammasomes, before dissecting the interactions between two processes in the context of cancer.


Autophagy is a “self-eating” process involving the degradation of, or dysfunctional cellular components through, fusion with lysosomes [20]. Several types of autophagy have been described, including macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) [21]. Macroautophagy is regarded as the canonical autophagy and involves a network of autophagy proteins that mediate the non-selective bulk degradation process (Fig. 1) [21, 22]. During this process, nutrient deprivation and metabolic stress trigger the activation of 5′-AMP-activated protein kinase (AMPK), which in turn activates unc-51-like autophagy-activating kinase (ULK). The ULK1 complex, consisting of ULK1, FIP200, ATG13, and ATG101, activates Beclin-1. Beclin-1 activation induces the formation and activation of class III phosphoinositide 3-kinase (PI3K) VPS34 complex, which is composed of Beclin-1, VPS34, VPS15, and ATG14L [23]. The VPS34 complex generates PI3P (phosphatidylinositol 3-phosphate)-rich subdomains on the endoplasmatic reticulum (ER) or ER-mitochondria contact sites, where PI3P-binding proteins can recruit the E3-like complex ATG16L1 (ATG5-12-16 L1). Subsequently, the ATG16L1 complex promotes the conjugation of ubiquitin-like molecule LC3 to phosphatidylethanolamine (PE) to generate LC3-PE (LC3-II), which is essential for the formation of double-membrane autophagosomes through membrane tethering and fusion. Autophagosomes are then fused with lysosomes, mediated by tethering factors, SNAP receptors (SNAREs), and phospholipids [24]. Finally, the cargo is degraded and recycled in the lysosomes (Fig. 1) [21].

Fig. 1

Overview of macroautophagy and mitophagy. Autophagy has dual roles in cancer, depending on the disease stage and tumor microenvironment. A summary of macroautophagy (autophagy) and mitophagy is shown. Autophagy can be divided into three steps: initiation, elongation, and maturation. In each step, several key players participate in the formation of phagophore (initiation), autophagosome elongation, and maturation (fusion of autophagosomes and lysosomes). In mitophagy, dysfunctional mitochondria are recognized by Parkin-dependent or Parkin-independent pathways. Ubiquitin, ubiquitin-binding proteins, and autophagy receptors, such as p62, NBR1, NDP52, and OPTN, are involved in the Parkin/PINK1-dependent mitophagy activation. In the Parkin-independent mitophagy pathway, several mitophagy receptors (Nix/BNIP3L, BNIP3, FUNDC1, BCL2L13, and FKBP8) direct damaged mitochondria to the LC3-mediated autophagy machinery


Selective autophagy involves the targeted degradation of specific cellular components and organelles. It has become evident that the ubiquitin, ubiquitin-binding proteins, and autophagy receptors, including sequestosome-1/p62, neighbor of BRCA1 (NBR1), nuclear dot protein 52 (NDP52), and optineurin (OPTN) are vital for the activation of selective autophagy in a context-dependent manner [17].

Mitophagy is a type of selective autophagy, playing an essential role in the maintenance of mitochondrial homeostasis [25]. Mitochondrial perturbation, reactive oxygen species (ROS), and oxidative stress can trigger mitophagy to degrade dysfunctional mitochondria as a mitochondrial quality control mechanism [25]. The PTEN-induced putative kinase protein 1 (PINK1) activates the E3 ubiquitin ligase Parkin, which translocates from the cytosol into the damaged mitochondria to ubiquitinate outer mitochondrial membrane (OMM) proteins, such as mitofusin (MFN) and voltage-dependent protein channel 1 (VDAC1). Furthermore, several mitophagy receptors have been identified, including BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (Nix/BNIP3L) [26], BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) [27], FUN14 domain-containing 1 (FUNDC1) [28], BCL2-like 13 (BCL2L13) [29], and FK506-binding protein 8 (FKBP8) [30]. Upon stress-induced activation, these mitophagy receptors are anchored in the OMM, recruiting ATG8 family members to the damaged mitochondria (Fig. 1) [31]. The expression of several mitophagy receptors and mediators is dysregulated in cancer, pinpointing the critical anti-tumor roles of mitophagy [32].

Overview of inflammasome activation

Inflammasomes are multiprotein complexes; upon formation and activation, they activate caspase-1, which promotes pyroptotic cell death (pyroptosis), as well as the maturation of IL-1β and IL-18 [33]. The innate sensor molecules of inflammasomes include different NLRs, absent in melanoma 2 (AIM2) and Pyrin. NLRP3 is the most well-characterized inflammasome, and the molecular and cellular events leading to its activation have been extensively reviewed elsewhere [34]. Herein, we briefly outline the mechanisms underlying the activation of NLRP3 and AIM2 inflammasomes (Fig. 2), as well as their crosstalk with autophagy in the context of cancer.

Fig. 2

NLRP3 and AIM2 inflammasome pathways. The NLRP3 inflammasome activation is mediated through two signals: Toll-like receptor (TLR)/tumor necrosis factor receptor (TNFR)-mediated NF-κB pathway activation or inflammasome complex assembly (NLRP3, ASC, and pro-caspase-1) triggered by particulate matter (lysosomal destabilization or cathepsin B release), mitochondrial ROS generation, intracellular calcium influx, or potassium efflux. The activated NLRP3 inflammasome promotes IL-1β and IL-18 maturation and induces pyroptotic cell death (osmotic lysis of cells). AIM2 inflammasome assembly is induced by the recognition of cytosolic DNA and leads to pyroptosis and IL-1β/IL-18 maturation

NLRP3 inflammasomes are sensor protein complexes composed of NLRP3 and the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC). ASC recruits pro-caspase-1, which is subsequently cleaved to caspase-1. The latter catalyzes the proteolytic maturation of IL-1β and IL-18 [34]. Although the mechanisms underlying NLRP3 inflammasome activation are not fully understood, various pathogens and danger signals have been shown to trigger its activation [33, 34]. NLRP3 inflammasome activation is believed to occur in two steps: the first signal (priming) induces NLRP3 activation and pro-IL-1β expression through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling and the second signal (activation) promotes NLRP3 inflammasome assembly. Due to the structural diversity of its ligands, NLRP3 inflammasome activation does not seem to be structure-dependent [34]. Instead, it is likely to be mediated via several molecular signaling pathways, including K+ efflux, Ca2+ signaling, mitochondrial ROS generation, and lysosomal rupture (Fig. 2) [33]. AIM2 is a member of the hematopoietic interferon-inducible nuclear proteins with a 200-amino-acid repeat (HIN-200) family; it induces inflammasome formation through recognition of aberrant and cytosolic double-stranded DNA (dsDNA). AIM2 inflammasomes also contain ASC and caspase-1, which are responsible for the maturation of IL-1β and IL-18 (Fig. 2) [35].

The activation of both NLRP3 and AIM2 inflammasomes results in inflammatory cell death, also known as pyroptosis, through the cleavage of gasdermin D (GSDMD) and activation of IL-1β and IL-18 (Fig. 2) [36, 37]. Pyroptosis can be induced by caspase-1/4/5/11, and caspase-4/5/11-mediated pyroptosis activates the noncanonical inflammasome pathway [36, 37]. Caspase-1-mediated pyroptosis is triggered by NLRP3 or AIM2 inflammasomes and involves the release of the pore-forming N-terminal fragment of GSDMD (GSDMD-NT) in the plasma membrane; the formation of pores facilitates the secretion of inflammatory cytokines and osmotic lysis of the cells (Fig. 2). These responses, and the release of IL-1β and IL-18, in particular, result in cell death and tissue damage [36, 37]. Recent studies highlighted that the modulation of GSDMD and pyroptosis can influence all stages of carcinogenesis, i.e., tumor cell proliferation, invasion, and metastasis [37, 38]. Both gasdermin E (GSDME) and GSDMD, important pyroptosis substrates, are also emerging targets as prognostic biomarkers for the management of various cancers [37, 39]. Small molecules that trigger or inhibit pyroptosis can lead to inhibition of tumor cells [38, 39]. However, it has been largely uncharacterized whether and how both GSDMD and GSDME are associated with the autophagy process while regulating progression or inhibition of tumorigenesis.

Crosstalk between inflammasome activation and autophagy in cancer

Accumulating evidence supports the importance of crosstalk between inflammasome activation and autophagy in numerous biological and pathological processes, particularly in infection and inflammation. Recent studies suggest that defects in this interplay have been linked to cancers, i.e., tumorigenesis, cancer stemness, and resistance to anti-cancer therapies. In the following sections, we describe several mechanisms and key players participating in the interplay between autophagy and inflammasomes to provide insight into the tumorigenesis, metastasis, and treatment of cancers (Fig. 3). Increasing understanding of the molecular mechanisms for the autophagy-inflammasome axis could aid in the design of improved anti-cancer therapeutics from the bench works to the clinical settings.

Fig. 3

Crosstalk between autophagy and inflammasome activation in cancer. The crosstalk between autophagy and inflammasome activation regulates multiple physiological and pathological responses, including cancer. Mitochondrial dysfunction and mitochondrial ROS generation can activate autophagy/mitophagy, as well as act as the second signal for inflammasome activation and pyroptosis. Dysfunctional autophagy results in excessive mitochondrial oxidative stress, leading to autophagic cell death, inflammasome activation, and pyroptosis. Elevated mitochondrial ROS levels can also promote oncogenesis, chemoresistance, and metastasis. Furthermore, mitochondria-associated membranes at the ER-mitochondria contact sites are signaling hubs for mitochondrial Ca2+ transfer from the ER to mitochondria through IP3R3s, mediating NLRP3 inflammasome activation in response to mitochondrial damage. IP3R3s are upregulated in various cancers

Mitochondrial dysfunction and ROS

Mitochondrial ROS are key upstream regulators of NLRP3 inflammasomes [40] and autophagy [41, 42]. Balance in the activation of inflammasomes and autophagy is essential for mitochondrial homeostasis (Fig. 3) [41, 42]. Dysfunctional autophagy results in mitochondrial oxidative stress and damage, leading to autophagic cell death, exaggerated activation of inflammasome, and pyroptosis [43, 44].

In cancer cells, intracellular redox signals modulate tumor progression and chemoresistance [45]. Imbalance in mitochondrial Ca2+ or ROS levels is frequently observed in most human cancers [45, 46]. Aberrant production of mitochondrial ROS can promote cancer cell proliferation, migration, or survival/apoptosis, depending on the context [47, 48]. Enhanced metabolism and increased ATP production via the electron transport chain are imperative for tumor progression and metastasis, with increasing mitochondrial ROS levels at the same time [47, 48]. Furthermore, since ATP-driven multidrug efflux is essential for the development of chemoresistance in cancer cells, hyperactivation of the electron transport chain and increased ROS production contribute to therapy resistance [45]. In addition to the enhanced mitochondrial ROS generation, ROS detoxification pathways are highly activated in tumors [45].

Moreover, excessive mitochondrial ROS generation during cancer treatment can induce a synergistic antitumor response during chemotherapy. A recent study showed that lung cancer apoptosis was increased in the condition of excessive mitochondrial fission and marked upregulation of mitochondrial ROS [49]. In addition, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) combination with gold nanoparticles led to a hyperactivation of mitochondrial fragmentation and mitochondrial dysfunction in non-small-cell lung cancer cells, thereby promoting apoptosis of cancer cells to TRAIL [50]. In another study, the anticancer responses of oxaliplatin were enhanced by combination with piperlongumine, a molecule promoting ROS in colorectal cancer [51]. In cholangiocarcinoma, a very aggressive cancer, mitochondrial division inhibitor-1 (Mdivi-1) sensitized cancer cells to cisplatin cytotoxicity with increased oxidative stress and inhibition of autophagosomes [52]. Emerging evidence suggests the effects of chemosensitizers in mitochondrial dysfunction and ROS generation to overcome chemoresistance in various cancer settings. Nevertheless, it is currently unclear whether hyper-activation of mitochondrial ROS by a variety of sensitizers directly or indirectly regulates the interplay between autophagy and inflammasomes in anti-cancer treatment. An ongoing paradigm of mitochondrial ROS generation in normal and cancer cells, as well as chemotherapeutic resistance and sensitization, is summarized in Fig. 4. A better understanding of the molecular mechanisms by which mitochondrial ROS link between autophagy and inflammasome activation in different types and stages of cancer cells may enable to offer improved treatment against chemoresistant tumors.

Fig. 4

The role of mitochondrial ROS in the regulation of the autophagy/inflammasome axis at MAMs in non-malignant cells, cancer cells, and chemosensitized cells. MAMs are signaling hubs, playing crucial roles in the crosstalk between autophagy and inflammasome activation, as well as intracellular Ca2+ signaling, mitochondrial lipid metabolism, and bioenergetics. Mitochondrial dysfunction and subsequent mitochondrial ROS generation activate autophagy/mitophagy, which negatively regulates NLRP3 inflammasome activation in non-malignant cells. Cancer cells are characterized by elevated mitochondrial ROS levels, accompanied by the upregulation of antioxidant machinery components. The role of mitochondrial ROS in the crosstalk between autophagy and inflammasome activation in cancer cells remains unclear. In chemosensitized cells, excessive production of mitochondrial ROS results in autophagic and pyroptotic cell death. Although the role of IP3R in the regulation of the autophagy/inflammasome axis remains unknown, IP3R inhibition can suppress tumor growth

Mitochondria-associated membranes

Mitochondria-associated membranes (MAMs) at the ER-mitochondria contact sites are crucial for the activation of NLRP3 inflammasomes and autophagy [15, 53, 54]. Importantly, autophagy activation at MAMs mediates the removal of dysfunctional or aged mitochondria, thereby inhibiting NLRP3 inflammasome activation [55]. The signaling events occurring at the ER-mitochondria contact sites appear to be important in determining the fate of the cell, regulating tumor progression [15].

MAMs are signaling hubs for intracellular Ca2+-dependent pathways that regulate lipid synthesis and mitochondrial bioenergetics [54]. Ca2+ transfer from the ER into mitochondria is considered critical for NLRP3 inflammasome activation by inducing mitochondrial damage [56]. In particular, type 3 inositol 1,4,5-trisphosphate (IP3) receptors (IP3R3s) located at MAMs mediate pro-apoptotic and anti-cancer effects [57]. Paradoxically, IP3R3 levels are elevated in cancer, and several IP3R3s have been implicated in oncogenesis and cancer cell survival [58,59,60]. Since many cancer cells rely on ER-mitochondrial Ca2+ fueling, inhibition of IP3Rs can suppress cancer cell proliferation and migration and promote cell death [61]. Although the mechanisms remain unclear, enhanced autophagy has been shown to mediate the anti-tumor effects of IP3R-targeting agents [62]. However, the role of IP3R modulation on inflammasome activation is yet to be elucidated. The role of mitochondrial ROS at MAMs for the regulation of the autophagy/inflammasome axis is illustrated in Fig. 4, in both non-malignant cells and cancer cells. Future studies are required to elucidate the relevance of IP3Rs in regulating autophagy, inflammasome activation, and cell death.

Double-stranded RNA-dependent protein kinase

The translation of mRNAs is closely linked to cancer cell proliferation, as well as tumor progression and metastasis [63]. Phosphorylation of the translation initiation factor eIF2 at serine 51 (hereafter referred to as eIF2α-P) is imperative for mRNA translation and is primarily mediated by the double-stranded RNA (dsRNA)-dependent protein kinase (PKR) [63]. PKR is a multifunctional protein, regulating autophagy and inflammasome activation, as well as promoting the extracellular release of high-mobility group box 1 (HMGB1) protein (Fig. 3) [64]. Although PKR was thought to be a tumor suppressor, several pro-tumorigenic functions of PKR has been demonstrated in various cancers, including colon, breast, and liver cancer [65]. However, the present understanding about the role of PKR in the connection between autophagy and inflammasome is still preliminary in terms of cancer. An example was reported in hepatocellular carcinoma. PKR is upregulated in hepatitis C virus (HCV)-related hepatocellular carcinoma [66] and promotes cancer cell growth by activating the MAPK pathway [65]. In addition to hepatocellular carcinoma cell growth, PKR induces autophagy and inflammasome activation in an HMGB1-dependent manner [65].

PKR interacts with the translation elongation factor eEF1A2, promoting cell survival and other malignant characteristics in preneoplastic precursor cells [67]. Thus, translation inhibitors targeting eIF4E have been investigated as anti-cancer agents in various hematologic malignancies [63]. The drug plitidepsin, which inhibits the interaction between eEF1A2 and PKR, has been shown to induce cancer cell death by activating the extrinsic apoptosis pathway [67]. In addition, PKR/eIF2α-P axis inhibition showed anti-tumor effects against HER2-positive breast cancer and gastric cancer [68]. Moreover, the eIF2α-phosphatase inhibitor SAL003 potentiated the anti-tumor effects of trastuzumab in HER2-positive tumor cells [68]. eIF2α-P levels have been proposed as a prognostic marker in HER2-positive breast cancer patients treated with trastuzumab [68]. Given the multifaceted role for PKR in different tumor entities [65, 67], further investigation into the involvement of autophagy-inflammasome pathway in the development of PKR-targeting anti-cancer therapeutic interventions is warranted.

Autophagy-related molecules

Numerous studies have shown that the autophagy gene UVRAG functions as a tumor suppressor. Notably, the use of transgenic mice that inducibly express UVRAG with a frameshift mutation (iUVRAGFS) uncovered several of the anti-tumor roles of UVRAG [69]. Importantly, the transgenic mice exhibited intestinal inflammatory responses and increased susceptibility to colitis-associated cancer in an NLRP3 inflammasome-dependent manner. In addition, iUVRAGFS mice were more prone to spontaneous tumorigenesis, which was associated with age-related autophagy suppression [69].

Immunity-related GTPases (IRGs), a family of interferon (IFN)-inducible GTPases, are required for innate immune responses against intracellular bacteria and protozoa [70]. IRGM/Irgm1 is involved in autophagy and has been implicated in Crohn’s disease. Recent studies have demonstrated that IRGM is a key negative regulator of NLRP3 inflammasome activation by interacting with NLRP3 and ASC and subsequently inhibiting inflammasome assembly [71]. In line with this, IRGM mediates the autophagic degradation of NLRP3 components [72]. However, there is still relatively less known regarding the function of IRGM in cancer. In AGBL2-overexpressing hepatocellular carcinoma cells, IRGM-mediated autophagy promoted cancer cell survival and proliferation [73]. Recent reports revealed that IRGM was upregulated in human glioma and functioned in glioma cell proliferation and autophagy [74]. Other studies showed the involvement of ATG7 and JNK2 in the connection with the autophagy-inflammasome pathway in the experimental model of cancers [75, 76]. In a rat insulinoma cell line, ATG7 induced autophagy in response to palmitic acid. It also induced cathepsin B (CTSB) expression, enhancing NLRP3-mediated IL-1β secretion and lipotoxicity [75], suggesting a link between autophagy overactivation and susceptibility to diabetic inflammation. Additionally, JNK2 is involved in stress-induced mitophagy and prevents the hyperactivation of inflammasomes by targeting the tumor suppressor ARF [76].

Indeed, the activation of autophagy/mitophagy, in particular, lysosomal function, is potentially increasing cancer growth and aggressiveness, as it can regulate mitochondrial metabolism [1]. Several lysosomal activity-inhibitory agents are currently being tested as therapeutic strategies for a variety of cancers. Most of these agents target master regulators of autophagy and lysosomal biogenesis, such as MiT/TFE transcription factors (MITF, TFEB, or TFE3) [77]. These proteins are able to shuttle between lysosomes and nucleus to regulate transcriptional responses in response to the change of nutrient and growth factor, thus affecting cancer biology [70]. Furthermore, tumor-derived autophagosomes can strongly activate innate immune responses and NLRP3 inflammasomes in the absence of LPS priming and are, therefore, being tested as therapeutic cancer vaccines [78]. The autophagosomes isolated from cancer cells are named as defective ribosomal products in blebs (Dribbles) can induce strong T cell responses and activate antiben-presenting cells, thus promoting adaptive immune responses against tumor cells and viruses [78]. Hence, these studies suggest that autophagy/mitophagy-associated molecules may be the major players in both tumorigenesis and anti-tumor immune responses (Fig. 3). Although there are numerous autophagy-related genes, it is still in its infancy to understand the in vitro and in vivo function of these genes in variety of cancers. Further investigations into the underlying mechanisms by which autophagy-related genes may impact inflammasome activation and pyroptosis are also needed to optimize therapeutic strategy.

PINK1/Parkin and HMGB1

Mounting evidence suggests the essential role of mitophagy in the prevention of inflammatory diseases and cancer. Notably, Parkin translocation is impaired in chronic obstructive pulmonary disease (COPD), leading to the accumulation of dysfunctional mitochondria [13]. Thus, defective mitophagy and mitochondrial dysfunction are believed to be involved in the development of COPD-associated lung cancer [13].

PINK1-PRKN/PARK2-mediated mitophagy has also been reported to suppress pancreatic tumor growth through the autophagic degradation of mitochondrial iron importers, including SLC25A37 and SLC25A28 [79, 80]. Genetic ablation of Pink1 or Park2 in mice increased susceptibility to oncogenic Kras-driven pancreatic cancer development [79]. Mechanistically, mitochondrial iron accumulation and subsequent AIM2 inflammasome activation promoted pancreatic tumorigenesis [79]. Notably, AIM2-induced HMGB1 release enhanced the expression of the immune checkpoint CD274/ programmed death-ligand 1 (PD-L1), accelerating pancreatic tumorigenesis [79]. Thus, the defects in mitophagy may amplify the inflammasome-mediated tumorigenesis through HMGB1, a key factor linking inflammasome and tumorigenesis.

Indeed, HMGB1 is involved in the expansion of hepatic progenitor cells and hepatic tumor progression in autophagy-deficient livers. Mechanistically, HMGB1 is released from autophagy-deficient hepatocytes through nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2)-mediated inflammasome activation [81]. These data highlight the role of HMGB1 in tumor progression and immunopathology, and that its extracellular release is dependent on inflammasome activation, which could be amplified in autophagy-defective cells (Fig. 3). However, there might be a positive feedback loop in the activation of inflammasome-autophagy axis by HMGB1. Previous study suggests that HMGB1-DNA complexes induced autophagy by binding to the receptor for advanced glycation endproducts (RAGE) and that autophagy negatively regulated AIM2 inflammasome activation [82]. Future innovative approaches based on mitophagy activation to tweak HMGB1 release and AIM2 inflammasome activation may be considered to develop potential therapeutic candidates against refractory tumors including pancreatic cancer.

TRIM11 and TRIM16 as key links between autophagy and inflammasomes

Secretory autophagy, rather than conventional autophagy involving lysosomes, is essential for IL-1β secretion. The secretory autophagy cargo IL-1β is recognized by tripartite motif-containing protein 16 (TRIM16), and its secretion is mediated by the interaction of SEC22B, syntaxin 3, and syntaxin 4 [83, 84]. TRIM16 plays a key role in the regulation of the p62-KEAP1-NRF2 system, particularly in the NRF2 stabilization and p62 expression in response to oxidative/proteotoxic stresses [85]. In addition, TRIM16 is essential for the NRF2/p62-mediated autophagy/aggrephagy activation, promoting protein homeostasis (proteostasis) and cancer cell survival during oxidative/proteotoxic stress (Fig. 3) [85, 86]. This action of TRIM16 is required for the protection of HeLa cell apoptosis and death from toxic misfolded proteins in vitro and in vivo [85]. Although these data suggest that TRIM16 is a prosurvival protein through the regulation of autophagy, NRF2-p62, and ubiquitin system [85], it has not been characterized if TRIM16 is involved in the regulation of inflammasome activation and pyroptosis while suppressing cancer cell cytotoxicity.

It is largely unknown that the roles of other TRIM members in anti-cancer or pro-cancer responses. Among TRIM members, TRIM11 was identified as an essential negative regulator of AIM2 inflammasome activation through the induction of selective autophagy (Fig. 3) [87], suggesting a regulator candidate of tumor cell survival and death. Since AIM2 inflammasome-associated DNA-sensing pathways are closely related to tumorigenesis [88], future studies are warranted to assess the role of TRIM11 in cancer.

Potential anti-cancer therapeutics targeting the crosstalk between autophagy and inflammasomes

Emerging evidence from in vitro and in vivo studies suggest the potential clinical value of autophagy-inflammasome axis modulators as anti-cancer agents. In the following sections, we summarize potential anti-cancer treatment strategies using agents that modulate the crosstalk between autophagy and inflammasome activation.

Effects of autophagy-modulating agents on inflammasomes

Silibinin, an anti-cancer agent used in breast cancer patients, has been shown to suppress cancer cell migration and invasion by interfering with ROS generation and suppressing NLRP3 inflammasome activation [89]. Numerous studies have also highlighted the autophagy-modulating effects of silibinin [90,91,92]; therefore, silibinin is considered a promising therapeutic approach for various cancers. Ergosterol peroxide, a molecule isolated from the fungus Phoma sp., strongly induced ROS-dependent autophagy and caspase-dependent apoptosis in human lung adenocarcinoma cells. Additionally, ergosterol peroxide treatment inhibited tumor cell proliferation and migration by attenuating NLRP3 inflammasome activity [93]. Ergosterol peroxide also synergized with the anti-tumor drug sorafenib, exerting strong cytotoxic effects in human lung adenocarcinoma cells [93]. Although ergosterol peroxide inhibited apoptosis in lung adenocarcinoma, it remains unclear whether ergosterol peroxide-induced autophagy suppresses inflammasome activity directly [93].

Poly (amidoamine) (PAMAM) dendrimers are a novel class of nanomaterials. Interestingly, they induced autophagy hepatocellular carcinoma HepG2 cells, negatively affecting cell survival [94]. The hydrophobic polyphenol curcumin exerted anti-tumor effects and activated autophagy in several cancers both in vitro and in vivo [95, 96]. Given its multifaceted roles in the regulation of inflammasome activation [97, 98], it would be interesting to assess whether the anti-cancer effects of curcumin are mediated by activation of autophagy or by modulation of inflammasomes and pyroptosis. Coptisine, a natural compound extracted from Coptis chinensis, exerted potent anti-cancer effects through activation of autophagy or NLRP3 inflammasomes [99,100,101]. Taken together, various small molecules and nanomaterials modulating autophagy and inflammasome activation are currently being tested as anti-cancer agents for numerous cancer types.

Resveratrol, a natural polyphenolic phytoalexin, may play a protective role against cancer, particularly colorectal and skin cancer [102]. Interestingly, resveratrol activates and inhibits autophagy in colorectal cancer and skin cancer, respectively [103, 104]. Resveratrol can induce apoptosis and inhibit angiogenesis, thereby suppressing tumor growth and metastasis [105]. Importantly, resveratrol induced autophagy in various in vitro and in vivo disease models, by activating AMPK [106,107,108,109]. However, the mechanisms underlying the autophagy- and inflammasome-modulating effects of resveratrol in the context of cancer remain unclear. Small molecules, including GL-V9 (AMPK activator), exhibited strong anti-inflammatory effects by activating autophagy and inducing NLRP3 degradation, preventing colitis-associated colorectal cancer through [110]. The small molecule andrographolide prevented colitis progression and colon cancer development by suppressing the activation of NLRP3 inflammasomes. Andrographolide also inhibited the mammalian target of rapamycin (mTOR) pathway and induced mitophagy in macrophages, subsequently inhibiting NLRP3 inflammasomes [111]. Therefore, targeting the AMPK-mTOR pathway may serve as a promising therapeutic strategy for inflammation-associated cancers. Autophagy-modulating agents and their influences on inflammasomes and cancer are summarized in Table 1.

Table 1 Agents/small molecules of linking autophagy to inflammasomes in cancers

Dual activators of inflammasomes and autophagy

Numerous agents have been reported to activate autophagy and inflammasomes, in addition to inhibiting tumorigenesis. The antimalarial drug dihydroartemisinin (DHA) activated AIM2/caspase-1 inflammasomes and induced autophagy, thereby suppressing hepatocellular carcinoma growth [112]. Additionally, DHA enhanced ROS generation by inducing DNA damage, contributing to the activation of autophagy [112]. Furthermore, the anti-tumor effects of mevalonate metabolism inhibitors, including statins and bisphosphonates, have been associated with their ability to suppress protein prenylation and thereby activate inflammasomes and autophagy [113,114,115]. Moreover, a recent study showed that the Trillium tschonoskii maxim saponin polyphyllin VI (PPVI) inhibited the proliferation of human non-small cell lung cancer cells by inducing pyroptosis, as well as apoptotic and autophagic cell death in a ROS-NLRP3 inflammasome-dependent way [116, 117]. However, the relationship between apoptotic and autophagic cell death after PPVI treatment remains unknown.

Recent studies showed that treatment with ceramide-1-phosphate (C1P) or ceramide-1-phosphate transfer protein inhibition (CPTP, involved in C1P trafficking) [118] induced autophagy and IL-1β/IL-18 secretion in human epithelial cells by activating NLRP3 inflammasomes [119]. Considering the role of C1P in the generation of arachidonic acid, a key mediator of cancer, it would be of high clinical relevance to determine the relationship between C1P-mediated eicosanoid production and C1P-mediated inflammasome and autophagy modulation.

Although the effects of the estrogen receptor (ER) ligand 17β-estradiol in autophagy have been controversial, several clinical trials are currently investigating its anti-cancer effects in breast cancer patients, in combination with autophagy modulators [120]. A recent study showed that 17β-estradiol suppressed hepatocellular carcinoma progression by inducing caspase-1-mediated pyroptosis and inhibiting autophagy [121]. However, estrogen/ERα-induced autophagy has been associated with papillary thyroid cancer cell survival [122]. Thus, further studies are required to elucidate the role of ER/17β-estradiol in tumorigenesis, as well as assess its potential as a therapeutic target in cancer. Small molecules activating both autophagy and inflammasomes are summarized in Table 2.

Table 2 Agents/small molecules for dual activation of autophagy and inflammasomes

Role of pathogen-mediated autophagy and inflammasome activation in cancer

Despite the links between infections and cancer, little is known about the molecular mechanisms underlying autophagy/inflammasome-mediated tumor progression in the context of an infection. As both autophagy and inflammasome pathways are strongly linked to innate immune system activation in response to various pathogens, numerous intracellular pathogens have developed strategies to escape from these responses [123]. Dysregulation of autophagy or inflammasomes may lead to defective host defense and harmful inflammatory responses during infection, exacerbating immunopathology [123]. In this session, we briefly discuss recent findings that the pathogen-mediated disturbance in the activation or inhibition of autophagy-inflammasome pathway and their consequences on the infection-associated initiation and progression of cancers.

HCV infection leads to the activation of inflammasomes and the production of pro-inflammatory cytokines, including IL-1α and IL-1β, thereby promoting inflammation, fibrosis, and carcinogenesis [124, 125]. HCV infection can cause progressive liver disease and hepatocellular carcinoma through NLRP3 inflammasome activation, which can be counteracted by autophagy activation under certain circumstances [124]. A recent study showed that HCV induced IRGM-mediated phosphorylation of ULK1 to facilitate viral genome replication, inducing autophagy [126]. The IRGM-mediated autophagy after HCV infection might contribute to the tumor-promoting effects of HCV.

Helicobacter Pylori, a pathogen linked to intestinal metaplasia and gastric cancer, can induce autophagy and inflammasome activation in the host [127,128,129]. Nevertheless, future studies are required to determine the relevance of autophagy/inflammasome activation in the carcinogenic effects of H. pylori. Additionally, human papillomaviruses (HPVs) suppressed IL-1β production in immortalized keratinocytes; the IL-1β production regulation was mediated by the HPV16 E6 oncoprotein at the post-translational level [130]. The inhibition of IL-1β production by HPV16 E6 may contribute to immune evasion and tumorigenesis [130]. Pathogen-mediated regulation of autophagy and inflammasome in connection with cancer are summarized in Table 3. A deeper understanding of the regulation of the inflammasome-autophagy axis by pathogens could enable the development of novel approaches to prevent or treat pathogen-associated cancers.

Table 3 Pathogen-associated regulation of autophagy and inflammasome in terms of carcinogenesis

Clinical trials assessing the anti-cancer effects of autophagy/inflammasome modulators

Several ongoing clinical studies are assessing the anti-cancer effects of modulators of either autophagy or inflammasome pathway. Much less is known about their potential usefulness in terms of the crosstalks between two processes. Nevertheless, recent and ongoing clinical trials of targeted approaches in the autophagy or inflammasome give us new insights into the exploration of dual regulation in designing anti-cancer therapeutics. Among the agents listed in Table 4, chloroquine and hydroxychloroquine are the most common autophagy inhibitors used as anti-cancer agents, mainly for the treatment of refractory cancers in combination with other chemotherapeutic agents or radiotherapy [131, 133,134,135,136,137]. Although some clinical trials were terminated early or showed negative results [138], numerous experimental and clinical studies showed promising effects in multiple myeloma, renal cell cancer, lymphoma, and pancreatic cancer regarding the use of autophagy inhibitors as anti-cancer agents (Table 4) [132, 135]. However, several questions remain unanswered regarding the selection of patients to examine the potential clinical usefulness of autophagy-targeting agents. The establishment of reliable and robust biomarkers, as well as dose optimization, would be imperative for the successful clinical development of autophagy modulators as anti-cancer therapies.

Table 4 Clinical trials to evaluate the safety and efficacy of targeting autophagy in cancer

Inflammasome/pyroptosis-modulating agents have also been investigated for their anti-cancer and anti-metastatic effects in a clinical setting. CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) showed that canakinumab, a human monoclonal antibody targeting IL-1β, reduced the incidence of lung cancer in patients with atherosclerosis, highlighting it as a promising approach to prevent lung cancer [139]. Based on CANTOS study, phase 2 and 3 studies are underway to validate the efficacy of canakinumab as an adjuvant or neo-adjuvant treatment in lung cancer (Table 5). The anti-cancer effects of the inflammasome inhibitors anakinra and thalidomide have been tested in numerous cancers including colon cancer, breast cancer, multiple myeloma, prostate cancer, and pancreatic cancer (Table 5) [142, 143, 145]. In lines with the ongoing clinical trials (Table 5), either inflammasome inhibitor monotherapy or in synergy with other anticancer therapy should be confirmed in future investigations. In addition, various drugs including P2X purinoceptor 7 (P2X7R)-antagonist, andrographolide, and dibenzylideneacetone have been tested as a therapeutic strategy targeting inflammasome in multiple cancers (summarized in Table 5) [140, 141, 144, 146,147,148,149]. Clinical studies showed that the combination of thalidomide with cytotoxic chemotherapy provided durable responses in patients with refractory multiple myeloma, while the combination of docetaxel and thalidomide prolonged the overall survival in metastatic androgen-independent prostate cancer patients [142, 145]. Thus, the combination of inflammasome modulators with conventional chemotherapeutic drugs could provide synergistic anti-tumor effects in patients with advanced cancer, including those with chemoresistant or metastatic disease. Future randomized phase III clinical trials are required to confirm the anti-tumor effects and safety of these inflammasome-targeting compounds.

Table 5 Clinical and preclinical trials for anti-cancer strategies based on the regulation of inflammasome

A recent preclinical study is disappointing in demonstration of the findings that tumor-intrinsic PD-L1-NLRP3 inflammasome activation promoted resistance to anti-PD-L1 immunotherapy in multiple tumor models; this effect was mediated by the recruitment of granulocytic myeloid-derived suppressor cells into the tumor microenvironment, suppressing anti-tumor immune responses [150]. Despite this, multiple ongoing trials are investigating the anti-tumor effects of the combination of anti-PD1 immune checkpoint blockade and canakinumab in colon cancer, breast cancer, and non-small cell lung carcinoma (summarized in Table 5). Thus, it should be noted that increased sensitivity to immunotherapy, and immune checkpoint blockade in particular, is associated with inflammasome activation-associated gene expression profiles in melanoma patients [151]. Recently, a TMEM176B inhibitor and a newly identified negative regulator of NLRP3 inflammasome have been proposed as strategies to improve the efficacy of immune checkpoint blockade [151]. Although the use of inflammasome-related biomarkers has been suggested for monitoring immunotherapy responses, their usefulness needs to be confirmed in large patient cohorts. Future studies are warranted to determine how best to implement the current treatment options in combination with agents targeting the autophagy-inflammasome axis, in order to continue pursuing novel anti-cancer therapeutic discovery.


Host immune responses to pathogens trigger both autophagy induction and inflammasome activation as a part of an innate immune response, aimed at combating the invading infectious agents. Similar to pathogens, tumor cells hijack host defense mechanisms, including autophagy and inflammasome activation, in an effort to escape immune surveillance. Dysregulation of autophagy or inflammasome activation is frequently observed in human cancers, potentially contributing to tumor progression. Nevertheless, the activation of these pathways could also suppress tumor growth, depending on the cancer type, disease stage, and tumor microenvironment. It is widely accepted that autophagy prevents excessive activation of inflammasomes; however, complex interactions occur between autophagy and inflammasome pathways. Emerging evidence suggests that in cancer cells, both autophagy and inflammasome activation are regulated by multiple cellular and biochemical cues, including mitochondrial ROS, autophagy/mitophagy-related molecules, PKR, and TRIM family members. Additionally, the communication between autophagy and inflammasomes may occur at specific intracellular organelles, such as MAMs, where signaling pathways define whether autophagy/inflammasome activation promotes or suppresses tumor growth.

It has become evident that modulation of the autophagy/inflammasome axis could provide clinical benefit in certain cancers, which are resilient to conventional treatments. Given the recent findings on the close relationship between autophagy and the inflammasome in several cancers, targeting both pathways might be a promising anti-cancer strategy. With the identification of an increasing number of autophagy/inflammasome modulators, we are just beginning to determine the potential clinical usefulness of autophagy/inflammasome-targeting to prevent or treat cancer. The clinical investigation of novel therapeutic interventions can be challenging, especially since the inflammasome and autophagy can have dual roles in cancer depending on the context. Besides, the crosstalk outcomes between the two pathways may be dynamic, depending on the tumor characteristics and the components of the tumor microenvironment. Thus, the development of personalized autophagy/inflammasome-targeting approaches might be required.

Availability of data and materials

Not applicable



Absent in melanoma 2


5′-AMP-activated protein kinase


Apoptosis-associated speck-like protein containing a CARD


BCL2-like 13


BCL2/adenovirus E1B 19 kDa protein-interacting protein 3


BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like


Double-stranded DNA


Estrogen receptor


FK506-binding protein 8


FUN14 domain-containing 1


Gasdermin D


High-mobility group box 1




Inositol 1,4,5-trisphosphate (IP3) receptors


Immunity-related GTPases


Mitochondria-associated membranes


Mammalian target of rapamycin


Neighbor of BRCA1


Nuclear dot protein 52


Nuclear factor kappa-light-chain-enhancer of activated B cells


NOD-like receptor


NOD-, LRR-, and pyrin domain-containing protein 3


Nuclear factor erythroid 2 (NFE2)-related factor 2


Outer mitochondrial membrane




Programmed death-ligand 1




Phosphoinositide 3-kinase


Phosphatidylinositol 3-phosphate


PTEN-induced putative kinase 1


Protein kinase RNA-activated or double-stranded RNA (dsRNA)-dependent protein kinase


Receptor for advanced glycation endproducts


Reactive oxygen species


Soluble NSF attachment proteins (SNAP) receptors


Toll-like receptor


Tumor necrosis factor receptor


Tripartite motif-containing protein


unc-51-like autophagy activating kinase 1


Voltage-dependent protein channel 1


  1. 1.

    White E. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42–6.

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61(5):667–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Chang JY, Yi HS, Kim HW, Shong M. Dysregulation of mitophagy in carcinogenesis and tumor progression. Biochim Biophys Acta Bioenerg. 2017;1858(8):633–40.

    CAS  PubMed  Google Scholar 

  4. 4.

    Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19(11):3466.

    PubMed Central  Google Scholar 

  5. 5.

    Lei Y, Zhang D, Yu J, Dong H, Zhang J, Yang S. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett. 2017;393:33–9.

    CAS  PubMed  Google Scholar 

  6. 6.

    He Q, Fu Y, Tian D, Yan W. The contrasting roles of inflammasomes in cancer. Am J Cancer Res. 2018;8(4):566–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Deswaerte V, Ruwanpura SM, Jenkins BJ. Transcriptional regulation of inflammasome-associated pattern recognition receptors, and the relevance to disease pathogenesis. Mol Immunol. 2017;86:3–9.

    CAS  PubMed  Google Scholar 

  8. 8.

    Velloso FJ, Trombetta-Lima M, Anschau V, Sogayar MC, Correa RG. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep. 2019;39(4):BSR20181709.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Saxena M, Yeretssian G. NOD-like receptors: master regulators of inflammation and cancer. Front Immunol. 2014;5:327.

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Cao X, Xu J. Insights into inflammasome and its research advances in cancer. Tumori. 2019;105(6):456–64.

    CAS  PubMed  Google Scholar 

  11. 11.

    Netea-Maier RT, Plantinga TS, van de Veerdonk FL, Smit JW, Netea MG. Modulation of inflammation by autophagy: consequences for human disease. Autophagy. 2016;12(2):245–60.

    CAS  PubMed  Google Scholar 

  12. 12.

    Fesus L, Demeny MA, Petrovski G. Autophagy shapes inflammation. Antioxid Redox Signal. 2011;14(11):2233–43.

    PubMed  Google Scholar 

  13. 13.

    Ng Kee Kwong F, Nicholson AG, Harrison CL, Hansbro PM, Adcock IM, and Chung KF. Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma? Eur Respir Rev. 2017;26(146):170040.

  14. 14.

    Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol. 2012;3:414.

    PubMed  Google Scholar 

  15. 15.

    Sassano ML, van Vliet AR, Agostinis P. Mitochondria-associated membranes as networking platforms and regulators of cancer cell fate. Front Oncol. 2017;7:174.

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Yun CW and Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19(11).

  17. 17.

    Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol. 2010;12(9):836–41.

    CAS  PubMed  Google Scholar 

  18. 18.

    Schreiber A, Peter M. Substrate recognition in selective autophagy and the ubiquitin-proteasome system. Biochim Biophys Acta. 2014;1843(1):163–81.

    CAS  PubMed  Google Scholar 

  19. 19.

    Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell. 2009;34(3):259–69.

    CAS  PubMed  Google Scholar 

  20. 20.

    Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–41.

    CAS  PubMed  Google Scholar 

  21. 21.

    Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2014;20(3):460–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Ryter SW, Cloonan SM, Choi AM. Autophagy: a critical regulator of cellular metabolism and homeostasis. Mol Cells. 2013;36(1):7–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol. 2013;15(7):741–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2018;14(2):207–15.

    CAS  PubMed  Google Scholar 

  25. 25.

    Yang X, Pan W, Xu G, Chen L. Mitophagy: a crucial modulator in the pathogenesis of chronic diseases. Clin Chim Acta. 2020;502:245–54.

    PubMed  Google Scholar 

  26. 26.

    Esteban-Martinez L, Sierra-Filardi E, McGreal RS, Salazar-Roa M, Marino G, Seco E, et al. Programmed mitophagy is essential for the glycolytic switch during cell differentiation. EMBO J. 2017;36(12):1688–706.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson AB. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol Chem. 2012;287(23):19094–104.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P, et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol. 2012;14(2):177–85.

    PubMed  Google Scholar 

  29. 29.

    Murakawa T, Yamaguchi O, Hashimoto A, Hikoso S, Takeda T, Oka T, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat Commun. 2015;6:7527.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Bhujabal Z, Birgisdottir AB, Sjottem E, Brenne HB, Overvatn A, Habisov S, et al. FKBP8 recruits LC3A to mediate Parkin-independent mitophagy. EMBO Rep. 2017;18(6):947–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Springer MZ, Macleod KF. In Brief: Mitophagy: mechanisms and role in human disease. J Pathol. 2016;240(3):253–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Drake LE, Springer MZ, Poole LP, Kim CJ, Macleod KF. Expanding perspectives on the significance of mitophagy in cancer. Semin Cancer Biol. 2017;47:110–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 2015;265(1):35–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Sharma BR, Karki R, Kanneganti TD. Role of AIM2 inflammasome in inflammatory diseases, cancer and infection. Eur J Immunol. 2019;49(11):1998–2011.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. 2020;38:567–95.

    CAS  PubMed  Google Scholar 

  37. 37.

    Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595.

    CAS  PubMed  Google Scholar 

  38. 38.

    Ruan J, Wang S, Wang J. Mechanism and regulation of pyroptosis-mediated in cancer cell death. Chem Biol Interact. 2020;323:109052.

    CAS  PubMed  Google Scholar 

  39. 39.

    Wang YY, Liu XL, Zhao R. Induction of pyroptosis and its implications in cancer management. Front Oncol. 2019;9:971.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Yu JW, Lee MS. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch Pharm Res. 2016;39(11):1503–18.

    CAS  PubMed  Google Scholar 

  41. 41.

    Roca-Agujetas V, de Dios C, Leston L, Mari M, Morales A, Colell A. Recent insights into the mitochondrial role in autophagy and its regulation by oxidative stress. Oxid Med Cell Longev. 2019;2019:3809308.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012;441(2):523–40.

    CAS  PubMed  Google Scholar 

  43. 43.

    Chen Z, Liu X, Ma S. The roles of mitochondria in autophagic cell death. Cancer Biother Radiopharm. 2016;31(8):269–76.

    CAS  PubMed  Google Scholar 

  44. 44.

    Yabal M, Calleja DJ, Simpson DS, Lawlor KE. Stressing out the mitochondria: mechanistic insights into NLRP3 inflammasome activation. J Leukoc Biol. 2019;105(2):377–99.

    CAS  PubMed  Google Scholar 

  45. 45.

    Kim EK, Jang M, Song MJ, Kim D, Kim Y, Jang HH. Redox-mediated mechanism of chemoresistance in cancer cells. Antioxidants (Basel). 2019;8(10):471.

    CAS  PubMed Central  Google Scholar 

  46. 46.

    Delierneux C, Kouba S, Shanmughapriya S, Potier-Cartereau M, Trebak M, Hempel N. Mitochondrial calcium regulation of redox signaling in cancer. Cells. 2020;9(2):432.

    CAS  PubMed Central  Google Scholar 

  47. 47.

    Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–80.

    CAS  PubMed  Google Scholar 

  48. 48.

    Porporato PE, Payen VL, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 2: mitochondria, lipid and amino acid metabolism. Cell Mol Life Sci. 2016;73(7):1349–63.

    CAS  PubMed  Google Scholar 

  49. 49.

    Chauhan SS, Toth RK, Jensen CC, Casillas AL, Kashatus DF, Warfel NA. PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer. Oncogene. 2020;39(12):2597–611.

    CAS  PubMed  Google Scholar 

  50. 50.

    Ke S, Zhou T, Yang P, Wang Y, Zhang P, Chen K, et al. Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells. Int J Nanomedicine. 2017;12:2531–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Chen W, Lian W, Yuan Y, Li M. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019;10(8):600.

    PubMed  PubMed Central  Google Scholar 

  52. 52.

    Tusskorn O, Khunluck T, Prawan A, Senggunprai L, Kukongviriyapan V. Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells. Biomed Pharmacother. 2019;111:109–18.

    CAS  PubMed  Google Scholar 

  53. 53.

    Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221–5.

    CAS  PubMed  Google Scholar 

  54. 54.

    van Vliet AR, Verfaillie T, Agostinis P. New functions of mitochondria associated membranes in cellular signaling. Biochim Biophys Acta. 2014;1843(10):2253–62.

    PubMed  Google Scholar 

  55. 55.

    Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, et al. NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell. 2016;164(5):896–910.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Murakami T, Ockinger J, Yu J, Byles V, McColl A, Hofer AM, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012;109(28):11282–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Sneyers F, Rosa N, Bultynck G. Type 3 IP3 receptors driving oncogenesis. Cell Calcium. 2020;86:102141.

    CAS  PubMed  Google Scholar 

  58. 58.

    Rezuchova I, Hudecova S, Soltysova A, Matuskova M, Durinikova E, Chovancova B, et al. Type 3 inositol 1,4,5-trisphosphate receptor has antiapoptotic and proliferative role in cancer cells. Cell Death Dis. 2019;10(3):186.

    PubMed  PubMed Central  Google Scholar 

  59. 59.

    Ueasilamongkol P, Khamphaya T, Guerra MT, Rodrigues MA, Gomes DA, Kong Y, et al. Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma. Hepatology. 2020;71(2):583–99.

    CAS  PubMed  Google Scholar 

  60. 60.

    Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, et al. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut. 2019;68(9):1676–87.

    CAS  PubMed  Google Scholar 

  61. 61.

    Bustos G, Cruz P, Lovy A, Cardenas C. Endoplasmic reticulum-mitochondria calcium communication and the regulation of mitochondrial metabolism in cancer: a novel potential target. Front Oncol. 2017;7:199.

    PubMed  PubMed Central  Google Scholar 

  62. 62.

    Kania E, Roest G, Vervliet T, Parys JB, Bultynck G. IP3 receptor-mediated calcium signaling and its role in autophagy in cancer. Front Oncol. 2017;7:140.

    PubMed  PubMed Central  Google Scholar 

  63. 63.

    Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol. 2011;8(5):280–91.

    CAS  PubMed  Google Scholar 

  64. 64.

    Kang R, Tang D. PKR-dependent inflammatory signals. Sci Signal. 2012;5(247):pe47.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Watanabe T, Imamura T, Hiasa Y. Roles of protein kinase R in cancer: potential as a therapeutic target. Cancer Sci. 2018;109(4):919–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Hiasa Y, Kamegaya Y, Nuriya H, Onji M, Kohara M, Schmidt EV, et al. Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol. 2003;98(11):2528–34.

    CAS  PubMed  Google Scholar 

  67. 67.

    Losada A, Munoz-Alonso MJ, Martinez-Diez M, Gago F, Dominguez JM, Martinez-Leal JF, et al. Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival. Br J Cancer. 2018;119(11):1410–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, et al. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. Nat Commun. 2019;10(1):2139.

    PubMed  PubMed Central  Google Scholar 

  69. 69.

    Quach C, Song Y, Guo H, Li S, Maazi H, Fung M, et al. A truncating mutation in the autophagy gene UVRAG drives inflammation and tumorigenesis in mice. Nat Commun. 2019;10(1):5681.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science. 2003;302(5645):654–9.

    CAS  PubMed  Google Scholar 

  71. 71.

    Mehto S, Jena KK, Nath P, Chauhan S, Kolapalli SP, Das SK, et al. The Crohn's disease risk factor IRGM limits NLRP3 inflammasome activation by impeding its assembly and by mediating its selective autophagy. Mol Cell. 2019;73(3):429–45 e7.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Mehto S, Chauhan S, Jena KK, Chauhan NR, Nath P, Sahu R, et al. IRGM restrains NLRP3 inflammasome activation by mediating its SQSTM1/p62-dependent selective autophagy. Autophagy. 2019;15(9):1645–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Wang LL, Jin XH, Cai MY, Li HG, Chen JW, Wang FW, et al. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma. Cancer Lett. 2018;414:71–80.

    CAS  PubMed  Google Scholar 

  74. 74.

    Xu Y, Liu R, Liao C, Liu J, Zhao H, Li Z, et al. High expression of immunity-related GTPase family M protein in glioma promotes cell proliferation and autophagy protein expression. Pathol Res Pract. 2019;215(1):90–6.

    CAS  PubMed  Google Scholar 

  75. 75.

    Li S, Du L, Zhang L, Hu Y, Xia W, Wu J, et al. Cathepsin B contributes to autophagy-related 7 (Atg7)-induced nod-like receptor 3 (NLRP3)-dependent proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line. J Biol Chem. 2013;288(42):30094–104.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Zhang Q, Kuang H, Chen C, Yan J, Do-Umehara HC, Liu XY, et al. The kinase Jnk2 promotes stress-induced mitophagy by targeting the small mitochondrial form of the tumor suppressor ARF for degradation. Nat Immunol. 2015;16(5):458–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Ferguson SM. Beyond indigestion: emerging roles for lysosome-based signaling in human disease. Curr Opin Cell Biol. 2015;35:59–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Xing Y, Cao R, Hu HM. TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles). Cell Death Dis. 2016;7(8):e2322.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Li C, Zhang Y, Cheng X, Yuan H, Zhu S, Liu J, et al. PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism. Dev Cell. 2018;46(4):441–55 e8.

    CAS  PubMed  Google Scholar 

  80. 80.

    Kang R, Xie Y, Zeh HJ, Klionsky DJ, Tang D. Mitochondrial quality control mediated by PINK1 and PRKN: links to iron metabolism and tumor immunity. Autophagy. 2019;15(1):172–3.

    CAS  PubMed  Google Scholar 

  81. 81.

    Khambu B, Huda N, Chen X, Antoine DJ, Li Y, Dai G, et al. HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers. J Clin Invest. 2018;128(6):2419–35.

    PubMed  PubMed Central  Google Scholar 

  82. 82.

    Liu L, Yang M, Kang R, Dai Y, Yu Y, Gao F, et al. HMGB1-DNA complex-induced autophagy limits AIM2 inflammasome activation through RAGE. Biochem Biophys Res Commun. 2014;450(1):851–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. 83.

    Kimura T, Jia J, Claude-Taupin A, Kumar S, Choi SW, Gu Y, et al. Cellular and molecular mechanism for secretory autophagy. Autophagy. 2017;13(6):1084–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Kimura T, Jia J, Kumar S, Choi SW, Gu Y, Mudd M, et al. Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. EMBO J. 2017;36(1):42–60.

    CAS  PubMed  Google Scholar 

  85. 85.

    Jena KK, Kolapalli SP, Mehto S, Nath P, Das B, Sahoo PK, et al. TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy. EMBO J. 2018;37(18):e98358.

    PubMed  PubMed Central  Google Scholar 

  86. 86.

    Jena KK, Mehto S, Kolapalli SP, Nath P, Sahu R, Chauhan NR, et al. TRIM16 governs the biogenesis and disposal of stress-induced protein aggregates to evade cytotoxicity: implication for neurodegeneration and cancer. Autophagy. 2019;15(5):924–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Liu T, Tang Q, Liu K, Xie W, Liu X, Wang H, et al. TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy. Cell Rep. 2016;16(7):1988–2002.

    CAS  PubMed  Google Scholar 

  88. 88.

    Briard B, Place DE, Kanneganti TD. DNA Sensing in the innate immune response. Physiology (Bethesda). 2020;35(2):112–24.

    PubMed  Google Scholar 

  89. 89.

    Si L, Fu J, Liu W, Hayashi T, Nie Y, Mizuno K, et al. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion. Mol Cell Biochem. 2020;463(1-2):189–201.

    CAS  PubMed  Google Scholar 

  90. 90.

    Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci. 2018;213:236–47.

    CAS  PubMed  Google Scholar 

  91. 91.

    Bai ZL, Tay V, Guo SZ, Ren J, Shu MG. Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP. Biomed Res Int. 2018;2018:6165192.

    PubMed  PubMed Central  Google Scholar 

  92. 92.

    Jiang C, Jin S, Jiang Z, Wang J. Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. Onco Targets Ther. 2016;9:6609–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. 93.

    Wu HY, Yang FL, Li LH, Rao YK, Ju TC, Wong WT, et al. Ergosterol peroxide from marine fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells. Sci Rep. 2018;8(1):17956.

  94. 94.

    Li Y, Wang S, Wang Z, Qian X, Fan J, Zeng X, et al. Cationic poly(amidoamine) dendrimers induced cyto-protective autophagy in hepatocellular carcinoma cells. Nanotechnology. 2014;25(36):365101.

    PubMed  Google Scholar 

  95. 95.

    Shakeri A, Cicero AFG, Panahi Y, Mohajeri M, Sahebkar A. Curcumin: a naturally occurring autophagy modulator. J Cell Physiol. 2019;234(5):5643–54.

    CAS  PubMed  Google Scholar 

  96. 96.

    Zhao G, Han X, Zheng S, Li Z, Sha Y, Ni J, et al. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells. Oncol Rep. 2016;35(2):1065–74.

    CAS  PubMed  Google Scholar 

  97. 97.

    Yu Y, Sun J, Wang R, Liu J, Wang P, Wang C. Curcumin management of myocardial fibrosis and its mechanisms of action: a review. Am J Chin Med. 2019;47(8):1675–710.

    CAS  PubMed  Google Scholar 

  98. 98.

    Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, et al. Curcumin: a double hit on malignant mesothelioma. Cancer Prev Res (Phila). 2014;7(3):330–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99.

    Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010;111(6):1426–36.

    CAS  PubMed  Google Scholar 

  100. 100.

    Wu J, Luo Y, Deng D, Su S, Li S, Xiang L, et al. Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review. J Cell Mol Med. 2019;23(12):7946–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, et al. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. Biomed Pharmacother. 2017;89:864–74.

    CAS  PubMed  Google Scholar 

  102. 102.

    Elshaer M, Chen Y, Wang XJ, Tang X. Resveratrol: an overview of its anti-cancer mechanisms. Life Sci. 2018;207:340–9.

    CAS  PubMed  Google Scholar 

  103. 103.

    Back JH, Zhu Y, Calabro A, Queenan C, Kim AS, Arbesman J, et al. Resveratrol-mediated downregulation of Rictor attenuates autophagic process and suppresses UV-induced skin carcinogenesis. Photochem Photobiol. 2012;88(5):1165–72.

    CAS  PubMed  Google Scholar 

  104. 104.

    Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa K, et al. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int J Oncol. 2012;40(4):1020–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. 105.

    Pourhanifeh MH, Abbaszadeh-Goudarzi K, Goodarzi M, Piccirillo SGM, Shafiee A, Hajighadimi S, et al. Resveratrol: a new potential therapeutic agent for melanoma? Curr Med Chem. 2019.

    Google Scholar 

  106. 106.

    Song J, Huang Y, Zheng W, Yan J, Cheng M, Zhao R, et al. Resveratrol reduces intracellular reactive oxygen species levels by inducing autophagy through the AMPK-mTOR pathway. Front Med. 2018;12(6):697–706.

    PubMed  Google Scholar 

  107. 107.

    Meng HY, Shao DC, Li H, Huang XD, Yang G, Xu B, et al. Resveratrol improves neurological outcome and neuroinflammation following spinal cord injury through enhancing autophagy involving the AMPK/mTOR pathway. Mol Med Rep. 2018;18(2):2237–44.

    CAS  PubMed  Google Scholar 

  108. 108.

    Zhao H, Chen S, Gao K, Zhou Z, Wang C, Shen Z, et al. Resveratrol protects against spinal cord injury by activating autophagy and inhibiting apoptosis mediated by the SIRT1/AMPK signaling pathway. Neuroscience. 2017;348:241–51.

    CAS  PubMed  Google Scholar 

  109. 109.

    Wu J, Li X, Zhu G, Zhang Y, He M, Zhang J. The role of Resveratrol-induced mitophagy/autophagy in peritoneal mesothelial cells inflammatory injury via NLRP3 inflammasome activation triggered by mitochondrial ROS. Exp Cell Res. 2016;341(1):42–53.

    CAS  PubMed  Google Scholar 

  110. 110.

    Zhao Y, Guo Q, Zhao K, Zhou Y, Li W, Pan C, et al. Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. Oncoimmunology. 2017;7(1):e1375640.

    PubMed  PubMed Central  Google Scholar 

  111. 111.

    Guo W, Sun Y, Liu W, Wu X, Guo L, Cai P, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy. 2014;10(6):972–85.

    PubMed  PubMed Central  Google Scholar 

  112. 112.

    Shi X, Wang L, Ren L, Li J, Li S, Cui Q, et al. Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells. Phytother Res. 2019;33(5):1413–25.

    CAS  PubMed  Google Scholar 

  113. 113.

    Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res. 2012;18(13):3524–31.

    CAS  PubMed  Google Scholar 

  114. 114.

    Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate. 2010;70(9):971–81.

    CAS  PubMed  Google Scholar 

  115. 115.

    Liao YH, Lin YC, Tsao ST, Lin YC, Yang AJ, Huang CT, et al. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation. J Leukoc Biol. 2013;93(2):289–99.

    CAS  PubMed  Google Scholar 

  116. 116.

    Teng JF, Mei QB, Zhou XG, Tang Y, Xiong R, Qiu WQ, et al. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-kappaB/NLRP3/GSDMD signal axis in non-small cell lung cancer. Cancers (Basel). 2020;12(1):193.

    CAS  PubMed Central  Google Scholar 

  117. 117.

    Teng JF, Qin DL, Mei QB, Qiu WQ, Pan R, Xiong R, et al. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer. Pharmacol Res. 2019;147:104396.

  118. 118.

    Simanshu DK, Kamlekar RK, Wijesinghe DS, Zou X, Zhai X, Mishra SK, et al. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature. 2013;500(7463):463–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  119. 119.

    Mishra SK, Gao YG, Deng Y, Chalfant CE, Hinchcliffe EH, Brown RE. CPTP: a sphingolipid transfer protein that regulates autophagy and inflammasome activation. Autophagy. 2018;14(5):862–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. 120.

    Xiang J, Liu X, Ren J, Chen K, Wang HL, Miao YY, et al. How does estrogen work on autophagy? Autophagy. 2019;15(2):197–211.

    CAS  PubMed  Google Scholar 

  121. 121.

    Wei Q, Zhu R, Zhu J, Zhao R, Li M. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells. Oncol Res. 2019;27(7):827–34.

    PubMed  Google Scholar 

  122. 122.

    Fan D, Liu SY, van Hasselt CA, Vlantis AC, Ng EK, Zhang H, et al. Estrogen receptor alpha induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases. J Clin Endocrinol Metab. 2015;100(4):E561–71.

    CAS  PubMed  Google Scholar 

  123. 123.

    Krakauer T. Inflammasomes, autophagy, and cell death: the trinity of innate host defense against intracellular bacteria. Mediators Inflamm. 2019;2019:2471215.

    PubMed  PubMed Central  Google Scholar 

  124. 124.

    Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol. 2018;10(1):1–7.

    PubMed  PubMed Central  Google Scholar 

  125. 125.

    Negash AA, Olson RM, Griffin S, Gale M Jr. Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation. PLoS Pathog. 2019;15(2):e1007593.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. 126.

    Hansen MD, Johnsen IB, Stiberg KA, Sherstova T, Wakita T, Richard GM, et al. Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M. Proc Natl Acad Sci U S A. 2017;114(17):E3462–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. 127.

    Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: emerging new paradigms. Biochim Biophys Acta Rev Cancer. 2018;1869(1):42–52.

    CAS  PubMed  Google Scholar 

  128. 128.

    Raju D, Hussey S, Ang M, Terebiznik MR, Sibony M, Galindo-Mata E, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142(5):1160–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. 129.

    Semper RP, Mejias-Luque R, Gross C, Anderl F, Muller A, Vieth M, et al. Helicobacter pylori-induced IL-1beta secretion in innate immune cells is regulated by the NLRP3 inflammasome and requires the cag pathogenicity island. J Immunol. 2014;193(7):3566–76.

    CAS  PubMed  Google Scholar 

  130. 130.

    Niebler M, Qian X, Hofler D, Kogosov V, Kaewprag J, Kaufmann AM, et al. Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog. 2013;9(8):e1003536.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. 131.

    Arnaout A, Robertson SJ, Pond GR, Lee H, Jeong A, Ianni L, et al. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Res Treat. 2019;178(2):327–35.

    CAS  PubMed  Google Scholar 

  132. 132.

    Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23(13):3307–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133.

    Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs. 2014;32(6):1269–77.

    CAS  PubMed  Google Scholar 

  134. 134.

    Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy. 2014;10(8):1415–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. 135.

    Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(7):993–8.

    PubMed  PubMed Central  Google Scholar 

  136. 136.

    Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(13):4402–10.

    PubMed  PubMed Central  Google Scholar 

  137. 137.

    Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10(8):1380–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  138. 138.

    Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19(6):637–8.

    PubMed  PubMed Central  Google Scholar 

  139. 139.

    Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–42.

    CAS  PubMed  Google Scholar 

  140. 140.

    Qian F, Xiao J, Hu B, Sun N, Yin W, Zhu J. High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum Pathol. 2017;64:61–8.

    CAS  PubMed  Google Scholar 

  141. 141.

    Zhai Z, Qu X, Yan W, Li H, Liu G, Liu X, et al. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Res Treat. 2014;144(1):33–45.

    CAS  PubMed  Google Scholar 

  142. 142.

    Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  143. 143.

    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.

    CAS  PubMed  Google Scholar 

  144. 144.

    Gao H, Wang J. Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-kappaB signaling pathway. Mol Med Rep. 2016;13(2):1827–32.

    CAS  PubMed  Google Scholar 

  145. 145.

    Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2532–9.

    CAS  PubMed  Google Scholar 

  146. 146.

    Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17(8):588–606.

    CAS  PubMed  Google Scholar 

  147. 147.

    Kim BH, Min YS, Choi JS, Baeg GH, Kim YS, Shin JW, et al. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling. Exp Mol Med. 2011;43(5):313–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  148. 148.

    Wu CY, Hua KF, Chu CL, Yang SR, Arbiser JL, Yang SS, et al. Tris DBA ameliorates accelerated and severe lupus nephritis in mice by activating regulatory T cells and autophagy and inhibiting the NLRP3 inflammasome. J Immunol. 2020;204(6):1448–61.

    CAS  PubMed  Google Scholar 

  149. 149.

    Diaz B, Ostapoff KT, Toombs JE, Lo J, Bonner MY, Curatolo A, et al. Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget. 2016;7(32):51569–80.

    PubMed  PubMed Central  Google Scholar 

  150. 150.

    Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130(5):2570–86.

    CAS  PubMed  Google Scholar 

  151. 151.

    Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, et al. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation. Cancer Cell. 2019;35(5):767–81 e6.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references


We are indebted to the current and past members of our Medical Research Center (i-MRC) for discussions and investigations that contributed to this article. We apologize to colleagues whose work and publications could not be referenced owing to space constraints.


This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (No. 2017R1A5A2015385) and by the framework of international cooperation program managed by the National Research Foundation of Korea (2015K2A2A6002008).

Author information




E-KJ and CC conceptualized the article; E-KJ, CC, WS, and PS wrote and reviewed the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Eun-Kyeong Jo.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The authors confirm their consent to publish the manuscript.

Competing interests

The authors declare that they have no competing interests.

HCV hepatitis C virus, VacA vacuolating cytotoxin A, cagPAI cag pathogenicity island, Helicobacter pylori H. pylori

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chung, C., Seo, W., Silwal, P. et al. Crosstalks between inflammasome and autophagy in cancer. J Hematol Oncol 13, 100 (2020).

Download citation


  • Inflammasome
  • Autophagy
  • Mitophagy
  • Mitochondrial ROS
  • Cancer